S 05338 – New YorkStatus: Inactive / Dead
Year Introduced: 2015
PHARMACEUTICAL PRICE TRANSAPRENY ACT: would require the disclosure of: (i) research and development costs for the drug, (ii) clinical trial and regulatory costs, (iii) materials, manufacturing, and administrations costs, (iv) research and development subsidies, grants, and other such support, (v) other costs (patents, etc.), and (vi) marketing and advertising costs. See Policy and Medicine Article on S05338.
Return to Database Search
© 2018- The SLIHCQ Database. Initial funding for this project was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.